{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:16:52Z","timestamp":1779110212422,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.bcp.2026.117730","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T16:16:53Z","timestamp":1768925813000},"page":"117730","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Effects of CYP3A4 variants and drug\u2013drug interactions on the metabolism of fexinidazole"],"prefix":"10.1016","volume":"247","author":[{"given":"Jinyu","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3673-4248","authenticated-orcid":false,"given":"Haoxin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruibin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenjian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren-ai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10110","key":"10.1016\/j.bcp.2026.117730_b0005","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/S0140-6736(17)31510-6","article-title":"Human African trypanosomiasis","volume":"390","author":"B\u00fcscher","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.bcp.2026.117730_b0010","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1007\/s00415-019-09425-7","article-title":"Update on human African trypanosomiasis (sleeping sickness)","volume":"266","author":"Kennedy","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.bcp.2026.117730_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115946","article-title":"The discovery of aryl-2-nitroethyl triamino pyrimidines as anti-Trypanosoma brucei agents","volume":"264","author":"Linciano","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2026.117730_b0020","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1172\/JCI200421052","article-title":"Human African trypanosomiasis of the CNS: current issues and challenges","volume":"113","author":"Kennedy","year":"2004","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.bcp.2026.117730_b0025","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S1474-4422(12)70296-X","article-title":"Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness)","volume":"12","author":"Kennedy","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bcp.2026.117730_b0030","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/7355_2011_17","article-title":"Kinetoplastid Parasites","author":"von Geldern","year":"2011","journal-title":"Third World Diseases"},{"issue":"1","key":"10.1016\/j.bcp.2026.117730_b0035","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/bmb\/lds031","article-title":"Management of trypanosomiasis and leishmaniasis","volume":"104","author":"Barrett","year":"2012","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.bcp.2026.117730_b0040","doi-asserted-by":"crossref","unstructured":"H, P.D.K., The Drugs of Sleeping Sickness: Their Mechanisms of Action and Resistance, and a Brief History. Trop Med Infect Dis, 2020. 5(1).","DOI":"10.3390\/tropicalmed5010014"},{"issue":"10116","key":"10.1016\/j.bcp.2026.117730_b0045","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0140-6736(17)32758-7","article-title":"Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial","volume":"391","author":"Mesu","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.bcp.2026.117730_b0050","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1039\/D4MD00426D","article-title":"Fexinidazole optimization: enhancing anti-leishmanial profile, metabolic stability and hERG safety","volume":"15","author":"Surur","year":"2024","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bcp.2026.117730_b0055","unstructured":"Administration, U.S.F.a.D., Prescribing Information for Fexinidazole Tablets. 2021, U.S. Food and Drug Administration: Silver Spring, MD, USA."},{"issue":"12","key":"10.1016\/j.bcp.2026.117730_b0060","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.1128\/AAC.00246-11","article-title":"Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness","volume":"55","author":"Kaiser","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.bcp.2026.117730_b0065","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02515-18","article-title":"Pharmacokinetic-Pharmacodynamic Assessment of the Hepatic and Bone Marrow Toxicities of the New Trypanoside Fexinidazole","volume":"63","author":"Watson","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.bcp.2026.117730_b0070","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40262-014-0136-3","article-title":"Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human african trypanosomiasis: first-in-human studies","volume":"53","author":"Tarral","year":"2014","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.bcp.2026.117730_b0075","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.bcp.2026.117730_b0080","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/BF02353475","article-title":"Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans","volume":"24","author":"Wilkinson","year":"1996","journal-title":"J. Pharmacokinet. Biopharm."},{"issue":"5","key":"10.1016\/j.bcp.2026.117730_b0085","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40262-013-0041-1","article-title":"Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations","volume":"52","author":"Ince","year":"2013","journal-title":"Clin. Pharmacokinet."},{"issue":"5","key":"10.1016\/j.bcp.2026.117730_b0090","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00008571-200007000-00001","article-title":"Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method","volume":"10","author":"Ozdemir","year":"2000","journal-title":"Pharmacogenetics"},{"issue":"2","key":"10.1016\/j.bcp.2026.117730_b0095","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/03602530902843483","article-title":"Polymorphism of human cytochrome P450 enzymes and its clinical impact","volume":"41","author":"Zhou","year":"2009","journal-title":"Drug Metab. Rev."},{"issue":"6","key":"10.1016\/j.bcp.2026.117730_b0100","first-page":"7083","article-title":"Polymorphisms and phenotypic analysis of cytochrome P450 3A4 in the Uygur population in northwest China","volume":"8","author":"Jin","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"3","key":"10.1016\/j.bcp.2026.117730_b0105","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.pharmthera.2007.09.004","article-title":"Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects","volume":"116","author":"Ingelman-Sundberg","year":"2007","journal-title":"Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.bcp.2026.117730_b0110","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.2217\/pgs.11.103","article-title":"Genetic polymorphisms in CYP3A4 are associated with withdrawal symptoms and adverse reactions in methadone maintenance patients","volume":"12","author":"Chen","year":"2011","journal-title":"Pharmacogenomics"},{"issue":"2","key":"10.1016\/j.bcp.2026.117730_b0115","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00008571-200203000-00006","article-title":"Common allelic variants of cytochrome P4503A4 and their prevalence in different populations","volume":"12","author":"Lamba","year":"2002","journal-title":"Pharmacogenetics"},{"issue":"3","key":"10.1016\/j.bcp.2026.117730_b0120","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1124\/dmd.123.001542","article-title":"Identification and Functional Assessment of eight CYP3A4 Allelic Variants *39-*46 Detected in the Chinese Han Population","volume":"52","author":"Qi","year":"2024","journal-title":"Drug Metab. Dispos."},{"issue":"5","key":"10.1016\/j.bcp.2026.117730_b0125","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1158\/0008-5472.CAN-05-3636","article-title":"Targeting Multiple Signaling Pathways by Green Tea Polyphenol (\u2212)-Epigallocatechin-3-Gallate","volume":"66","author":"Khan","year":"2006","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.117730_b0130","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0304-3835(93)90026-6","article-title":"Enhancement of gap junctional intercellular communication in tumor promoter-treated cells by components of green tea","volume":"69","author":"Sigler","year":"1993","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.bcp.2026.117730_b0135","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/10408690390826464","article-title":"Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions","volume":"43","author":"Higdon","year":"2003","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"10.1016\/j.bcp.2026.117730_b0140","doi-asserted-by":"crossref","first-page":"440","DOI":"10.2741\/2691","article-title":"EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer","volume":"13","author":"Shankar","year":"2008","journal-title":"Front. Biosci."},{"issue":"3","key":"10.1016\/j.bcp.2026.117730_b0145","doi-asserted-by":"crossref","first-page":"244","DOI":"10.2133\/dmpk.DMPK-12-RG-101","article-title":"Effects of green tea catechins on cytochrome P450 2B6, 2C8, 2C19, 2D6 and 3A activities in human liver and intestinal microsomes","volume":"28","author":"Misaka","year":"2013","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.bcp.2026.117730_b0150","doi-asserted-by":"crossref","first-page":"188","DOI":"10.18433\/J3MS5C","article-title":"Inhibitory Effects of eight Green Tea Catechins on Cytochrome P450 1A2, 2C9, 2D6, and 3A4 Activities","volume":"19","author":"Satoh","year":"2016","journal-title":"J. Pharm. Pharm. Sci."},{"issue":"12","key":"10.1016\/j.bcp.2026.117730_b0155","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s12272-009-2209-7","article-title":"Effects of oral epigallocatechin gallate on the pharmacokinetics of nicardipine in rats","volume":"32","author":"Choi","year":"2009","journal-title":"Arch. Pharm. Res."},{"issue":"2","key":"10.1016\/j.bcp.2026.117730_b0160","first-page":"105","article-title":"Pharmacokinetic and chemoprevention studies on tea in humans","volume":"64","author":"Chow","year":"2011","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2026.117730_b0165","unstructured":"Additives, E.P.o.F., et al., Scientific opinion on the safety of green tea catechins. EFSA J, 2018. 16(4): p. e05239."},{"key":"10.1016\/j.bcp.2026.117730_b0170","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3389\/fphar.2019.00591","article-title":"Enzymatic Activities of CYP3A4 Allelic Variants on Quinine 3-Hydroxylation In Vitro","volume":"10","author":"Zhou","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"10","key":"10.1016\/j.bcp.2026.117730_b0175","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/s41401-020-0389-3","article-title":"Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer","volume":"41","author":"Liu","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bcp.2026.117730_b0180","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2022.907986","article-title":"The Influence of EGCG on the Pharmacokinetics and Pharmacodynamics of Bisoprolol and a New Method for Simultaneous Determination of EGCG and Bisoprolol in Rat Plasma","volume":"9","author":"Zeng","year":"2022","journal-title":"Front. Nutr."},{"issue":"119","key":"10.1016\/j.bcp.2026.117730_b0185","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003326","article-title":"The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis","volume":"4","author":"Wyllie","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bcp.2026.117730_b0190","unstructured":"Bustin, S., et al., The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments. CHINESE VERSION. Overseas Laboratory Medicine, 2010. 3: p. 15-24."},{"issue":"7","key":"10.1016\/j.bcp.2026.117730_b0195","first-page":"e999","article-title":"Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study. Lancet Glob","volume":"9","author":"Kande Betu","year":"2021","journal-title":"Health"},{"key":"10.1016\/j.bcp.2026.117730_b0200","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.2147\/DDDT.S152366","article-title":"Functional assessment of CYP3A4 allelic variants on lidocaine metabolism in vitro","volume":"11","author":"Fang","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"issue":"11","key":"10.1016\/j.bcp.2026.117730_b0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006980","article-title":"Insights into antitrypanosomal drug mode-of-action from cytology-based profiling","volume":"12","author":"Thomas","year":"2018","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"6","key":"10.1016\/j.bcp.2026.117730_b0210","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/jeu.12408","article-title":"Differences in the Detection of BrdU\/EdU Incorporation Assays Alter the Calculation for G1, S, and G2 Phases of the Cell Cycle in Trypanosomatids","volume":"64","author":"da Silva","year":"2017","journal-title":"J. Eukaryot. Microbiol."},{"key":"10.1016\/j.bcp.2026.117730_b0215","unstructured":"Naqvi, S. and R. Camden, Evaluation of zinc and green tea extract supplementation on reduction in symptom duration and severity associated with community respiratory viral infections: a randomized control trial (ZiPhenol Study). 2023."},{"issue":"9","key":"10.1016\/j.bcp.2026.117730_b0220","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23094485","article-title":"Examination of the Impact of CYP3A4\/5 on Drug-Drug Interaction between Schizandrol a\/schizandrol B and Tacrolimus (FK-506): a Physiologically based Pharmacokinetic Modeling Approach","volume":"23","author":"He","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2026.117730_b0225","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1124\/jpet.104.076836","article-title":"Two major grapefruit juice components differ in time to onset of intestinal CYP3A4 inhibition","volume":"312","author":"Paine","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.117730_b0230","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00204-020-02939-4","article-title":"Cross-species analysis of hepatic cytochrome P450 and transport protein expression","volume":"95","author":"Hammer","year":"2021","journal-title":"Arch. Toxicol."},{"issue":"5","key":"10.1016\/j.bcp.2026.117730_b0235","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S1734-1140(13)71482-8","article-title":"Effect of antidepressant drugs on cytochrome P450 2C11 (CYP2C11) in rat liver","volume":"65","author":"Wojcikowski","year":"2013","journal-title":"Pharmacol. Rep."},{"issue":"3","key":"10.1016\/j.bcp.2026.117730_b0240","first-page":"353","article-title":"Differential induction of rat hepatic cytochromes P450 3A1, 3A2, 2B1, 2B2, and 2E1 in response to pyridine treatment","volume":"29","author":"Kim","year":"2001","journal-title":"Drug Metab. Dispos."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226000614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226000614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T12:59:48Z","timestamp":1779109188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226000614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":48,"alternative-id":["S0006295226000614"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117730","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of CYP3A4 variants and drug\u2013drug interactions on the metabolism of fexinidazole","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117730","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117730"}}